Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of second-line treatment of bortezomib in
advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive
bortezomib while the other half will receive best supporting care.